Citations

Clear

144 citation(s) found for "Hopkins, David".

Practical application of pressure-volume loop analysis in a swine model of medical cardiac arrest
Jodłowski, Grzegorz , Rousseau, Mathieu, Jacobs, J F, Nelson, J, Dvir, May , Walker, P F, Morrison, J J, Stonko, David P. , Morrison, Jonathan J

Mayo Clinic

European Heart Journal | February 4, 2026 | Volume: 46 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehaf784.2190 Get It

Abstract Introduction Cardiac arrest (CA) is the sudden cessation of cardiac activity, leading to haemodynamic collapse and high mortality. Advanced life support (ALS) standardises resuscitation, but the post-return of spontaneous circulation (ROSC) period remains turbulent and poorly understood. Up to 50% of patients who achieve ROSC struggle to maintain spontaneous circulation, leading to re-arrest, typically within minutes. Post-cardiac arrest syndrome (PCAS), involving brain injury and ischaemia-reperfusion injury, plays a key role in re-arrest. Pressure-volume loop (PVL) analysis offers insight into load-independent cardiac biomechanics in the post-ROSC period. The aim of this study is to explore the feasibility of PVL analysis in a swine model of CA. Methods This swine study utilised a ventricular fibrillation (VF) cardiac arrest model in combination with PVL analysis. The experiment included four phases: animal preparation, VF induction, resuscitation, and post-ROSC care. Yorkshire swine (45-70 kg) were sedated, anaesthetised, and VF was induced via an endocavitary electrode attached to a battery. After that, the animals were divided into 3-minute and 6-minute arrest groups before commencing ALS. Standard ALS protocols were followed, including CPR, defibrillation, and drug administration. If ROSC was obtained, animals underwent a 3-hour critical care period. Cardiac indices were compared between baseline and end-of-study values. Results Eight adult Yorkshire swine were enrolled in the study, with a mean weight of 50.2 ± 2.9 kg. VF induction was successfully achieved, and PVL data were collected in all animals except one, establishing a successful porcine VF CA model. In the resuscitation phase, all animals in the 3-minute group achieved ROSC, as opposed to one in the 6-minute group. Post-ROSC metabolic changes included acidaemia, elevated lactate and potassium, partially resolving by study end. Right ventricle PVL data were unreliable, while left ventricle PVL was reliable in 3 of 5 ROSC animals. Preload-recruitable stroke work (PRSW) data were found to be more reliable than the End-Diastolic Pressure-Volume Relationship (ESPVR), with a significant increase in LV PRSW of 34 ± 12% observed post-ROSC in all surviving animals (p<0.001). Discussion This study demonstrates the feasibility of applying PVL analysis to a post-ROSC swine model of cardiac arrest (CA). As expected, warm ischaemic time predicted ROSC, but PVL analysis offered valuable insights into load-independent parameters. While data quality issues hindered ESPVR analysis, PRSW was successfully evaluated, revealing a significant increase post-ROSC, highlighting its potential to guide the development of future therapeutic targets for post-ROSC interventions. The small sample size and technical challenges limited the scope of conclusions, emphasising the need for larger studies.Kaplan-Meier Curve and cycles to ROSC (A) LV PVL, (B) PRSW Pre and Post-ROSC
Standard Elements in Studies of Adverse Events and Medical Error: the SESAME statement
Griffey, Richard T. , Unbeck, Maria , Stockwell, David C. , Adler, Lee, Ancona, Rachel M. , Classen, David, Schneider, Ryan M. , Rutjes, Anne Wilhelmina Saskia , Carpenter, Christopher R. , Rutjes, Anne WS , Carpenter, Christopher R , Griffey, Richard T , Unbeck, Maria

Mayo Clinic

BMJ Quality & Safety | January 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: bmjqs-2025-019458

10.1136/bmjqs-2025-019458 | PMID 41577438 Get It

Variability and persistent gaps in reporting have been consistently observed across studies evaluating adverse events in healthcare, dating back to the early days of the patient safety movement. Incomplete descriptions—particularly missing details regarding study design, conduct, methodologies and applied definitions—impede interpretation, hinder critical appraisal and limit reproducibility. These deficiencies not only obstruct a shared understanding of findings but also diminish the overall impact such studies may have on patient safety initiatives and policy development. To address these challenges and enhance the quality of reporting, we developed the SESAME (Standard Elements in Studies of Adverse Events and Medical Error) reporting guideline. SESAME is a 44-item checklist designed to support comprehensive and standardised reporting in studies evaluating potential patient harm. The guideline was developed over a 2-year period by an international, multidisciplinary panel through a consensus-driven process aligned with Enhancing the QUAlity and Transparency Of Health Research Network standards.
The Anxious Bipolar Phenotype: Clinical Complexity and Treatment Resistance
Singh, Balwinder, Ho, Ada Man-Choi, Coombes, Brandon, Romo-Nava, Francisco, CUÉLLAR-BARBOZA, Alfredo B., Gardea-Reséndez, Manuel, Bond, David J. , Prieto, Miguel, Pendegraft, Richard, McElroy, Susan, Biernacka, Joanna, Frye, Mark, Bond, David J , Singh, Balwinder , Ho, Ada Man‐Choi , Coombes, Brandon J. , Romo‐Nava, Francisco , Cuéllar‐Barboza, Alfredo B. , Gardea‐Resendez, Manuel , Prieto, Miguel L. , Veldić, Marin , McElroy, Susan L. , Biernacka, Joanna M. , Frye, Mark A.

Mayo Clinic

No container title available | January 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8503080/v1 | PMID 41646373 Get It

Abstract Background Anxiety disorders (ANX) affect 30–60% of individuals with bipolar disorder (BD), yet limited research has systematically examined clinical characteristics and treatment patterns in this comorbid population. This study investigated demographic, clinical, and pharmacotherapeutic differences between individuals with BD with and without comorbid ANX. Methods Cross-sectional data from 2,225 adults with BD enrolled in the Mayo Clinic Bipolar Disorder Biobank were analyzed. Participants were assessed for comorbid ANX, demographics, clinical characteristics, medication use, and treatment response using the Alda-A scale. Results Overall, 61% (n = 1,366) had comorbid ANX. Individuals with BD + ANX were younger (40.4 vs. 43.6 years, p < 0.001), more likely female (66.6% vs. 54.8%, p < 0.001), and exhibited higher rates of rapid cycling (64.2% vs. 45.2%, p < 0.001), suicide attempts (40.4% vs. 24.8%, p < 0.001), substance use disorders (63.5% vs. 54.8%, p < 0.001), and somatic comorbidities (MCIRS: 6.68 vs. 5.42, p < 0.001). Pharmacotherapeutically, BD + ANX individuals were less likely to receive lithium (37.1% vs. 47.8%, p = 0.005) and valproic acid (21.7% vs. 29.6%, p = 0.047), but more likely to receive antidepressants (53.8% vs. 39.5%, p < 0.001), benzodiazepines (39.9% vs. 26.6%, p < 0.001), and gabapentinoids (8.5% vs. 4.5%, p < 0.001). Notably, 17.3% of BD + ANX individuals received antidepressants without mood stabilizer coverage. Treatment response (Alda-A) scores were significantly lower in BD + ANX for lithium (4.91 vs. 6.05, p < 0.001), mood-stabilizing anticonvulsants (5.09 vs. 6.22, p < 0.001), and second-generation antipsychotics (4.67 vs. 5.73, p < 0.001). Similar patterns were observed in both BD-I and BD-II subtypes. Conclusions Individuals with BD + ANX represent a more severely affected subgroup with distinct prescribing patterns favoring antidepressants over mood stabilizers and attenuated mood stabilizers response. These findings highlight the need for anxiety-informed treatment algorithms recognizing anxiety comorbidity as a negative prognostic factor.
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma
Colman, Howard , Lombardi, Giuseppe , Wong, Eric T. , Walbert, Tobias , Lassman, Andrew B. , Peereboom, David M. , Kizilbash, Sani H. , Matsuoka, Carlos Kamiya , Pitz, Marshall , Desjardins, Annick , Kumthekar, Priya , Mason, Warren , Pellerino, Alessia , Butowski, Nicholas , Hamza, Mohamed A. , Lallana, Enrico C., Uhlmann, Erik J. , Welsh, Liam , Wen, Patrick Y. , Dietrich, Jörg , Wang, Chao , Levin, Victor A. , Lassman, Andrew B , Peereboom, David M , Kizilbash, Sani H , Kamiya-Matsuoka, Carlos , Pitz, Marshall W , Strowd, Roy E , Desjardins, Annick , Kumthekar, Priya , Mason, Warren , Pellerino, Alessia , Soffietti, Riccardo , Butowski, Nicholas A , Forsyth, Peter A , Hamza, Mohamed A , Hau, Peter , Nabors, Louis Burt , Uhlmann, Erik J , Welsh, Liam C , Wen, Patrick Yung , Dietrich, Jorg , Wang, Chao , Levin, Victor A , Colman, Howard , Eoli, Marica , Strowd, Roy E. , Soffietti, Riccardo , Hau, Peter , Nabors, Burt , Piccioni, David Eric , Lombardi, G

Mayo Clinic

Journal of Clinical Oncology | December 1, 2025 | Volume: 44 | Issue: 8 | Pages: 641-652

10.1200/jco-25-01204 | PMID 41325560 Get It

PURPOSE STELLAR (ClinicalTrials.gov identifier: NCT02796261 ) was a phase III, randomized, open-label trial of eflornithine + lomustine versus lomustine monotherapy in patients with recurrent grade 3 astrocytoma. METHODS At trial initiation, eligibility criteria included: age ≥18 years, anaplastic astrocytoma (2016 WHO CNS Tumor classification [WHO CNS4]), first recurrence ≥6 months after radiation and temozolomide (TMZ), Karnofsky performance status ≥70, and no imaging findings consistent with grade 4 glioblastoma. Random assignment (1:1) was stratified by isocitrate dehydrogenase ( IDH ) mutation, age, resection extent, and geography. Patients received eflornithine (2.8 g/m 2 orally, every 8 hours [2 weeks on, 1 week off]) + lomustine (90 mg/m 2 orally, once every 6 weeks), or lomustine monotherapy (110 mg/m 2 once every 6 weeks). The primary end point was overall survival (OS). RESULTS Among 343 patients randomly assigned across 74 sites in eight countries, there was no difference in survival between eflornithine + lomustine and lomustine monotherapy (median OS 23.4 v 20.3 months, hazard ratio [HR], 0.94). Following changes in classification and grading in the 2021 WHO CNS5, a subset analysis of patients with IDH- mutant, grade 3 astrocytoma (n = 196), defined in 2024, before unblinding, showed clinically meaningful improvements in median OS with eflornithine + lomustine versus lomustine monotherapy (34.9 v 23.5 months, HR, 0.64) and median progression-free survival (PFS, 15.8 v 7.2 months, HR, 0.57). No differences were observed among patients with CNS grade 4 disease. Grade ≥3 treatment-emergent adverse events of relevance were related to reversible myelosuppression (eflornithine + lomustine 42% v lomustine monotherapy 29% of patients) and hearing impairment (24% v 0%). No new safety signals were identified. CONCLUSION Clinically meaningful improvements were observed; eflornithine + lomustine doubled PFS and improved OS in patients with recurrent IDH -mutant, grade 3 astrocytoma, but not grade 4 tumors, after prior radiotherapy and TMZ, consistent with its cytostatic mechanism of action.
Convalescent plasma for COVID-19: planning for the next pandemic using the worldwide experience
Mattoon, Ellie Rose , Sullivan, David , Focosi, Daniele , Casadevall, Arturo , Mattoon, Ellie R , Sullivan, David J , Focosi, Daniele , Casadevall, Arturo , Joyner, Michael J. , Franchini, Massimo

Mayo Clinic

Clinical Microbiology Reviews | November 25, 2025 | Volume: 39 | Issue: 1 | Pages: No page available

10.1128/cmr.00060-24 | PMID 41288364 Get It

SUMMARY COVID-19 convalescent plasma (CCP) was the first specific therapy deployed for treating SARS-CoV-2 infection. CCP was successfully deployed in both resource-poor and resource-rich countries, establishing that convalescent plasma (CP) is a feasible option for combating the next pandemic. CCP reduced mortality and progression to hospitalization when used early in the disease with high-titer units. This knowledge was gained from a worldwide effort that included more than 50 countries. However, the deployment of CCP was haphazard and varied among countries. Clinical studies suffered from a lack of standardization regarding study design, CCP antibody dosing, timing of administration, and participant disease severity. Unfortunately, the hard-won knowledge from the serum therapy era in the early 20th century, which indicated that effective antibody therapy requires early use in the disease with a sufficient antibody dose, was largely forgotten. Many studies tested CCP late in the disease or without sufficient antibody titer and thus reported negative findings. Trial heterogeneity made it difficult to combine the results of studies. However, despite tremendous heterogeneity in study design and participant populations, meta-analysis revealed strong signals of efficacy when given early with high antiviral-specific antibody levels. When the next pandemic occurs, humanity is likely to resort to CP again. To avoid another chaotic rollout, planning for CP use should begin well before that emergency arrives and must involve both physician education on the principles of antibody therapy and clinical trial designs that test its efficacy in optimal conditions, which include early use with sufficient antibody doses.
NODG-01 EVALUATING THE CURRENT NEURO-ONCOLOGY CAPACITY IN SUB-SAHARAN AFRICA: A QUESTIONNAIRE-BASED SURVEY
Zerd, Francis , Cheserem, Beverly , Ghomsi, Nathalie , Eckel‐Passow, Jeanette E. , Jenkins, Robert B. , Schroeder, Kristin, Zerd, Francis , Odukoya, Lateef A , Darko, Kwadwo , LLEWELLYN, HENRY J. , Kamson, David , Fonkem, Ekokobe , Schroeder, Kristin

Mayo Clinic

Neuro-Oncology Advances | November 9, 2025 | Volume: 7 | Issue: Supplement_5 | Pages: No page available

10.1093/noajnl/vdaf213.046 Get It

Abstract Background Central nervous system (CNS) tumors are a significant cause of morbidity and mortality in sub-Saharan Africa (SSA). To date, no large-scale efforts have focused on brain tumor genetics within this region. This study aimed to assess and map the current neuro-oncology capacity in SSA, including workforce availability and existing services for brain tumor registries and biobanks. The results represent the final analysis representing respondents from 70 healthcare institutions. Methods This cross-sectional study utilized an online survey to collect data from healthcare professionals involved in CNS tumor care across SSA through the Society for Neuro-Oncology SSA (SNOSSA). The survey gathered information on the availability of neuro-oncology practitioners, neuropathology and molecular diagnostic capacity, brain tumor management, cancer registries, and biobanking of specimens. Purposive sampling was used to identify participants, with the questionnaire provided in English, French, and Swahili. Results A total of 145 respondents from 22 countries and 70 healthcare institutions participated. Among the 70 institutions, neurosurgery was available in 89%, anatomic pathology in 74%, and medical oncology in 71%. For radiologic evaluation, 64% of institutions reported having both CT and MRI, while 17% had CT only. Molecular testing through IHC or NGS was available in 46% of institutions. Multidisciplinary tumor boards for CNS cases were present in 86% of institutions. General cancer registries were available in 66% of institutions, while 29% had brain tumor-specific registries, and 10% maintained brain tumor biorepositories. Conclusion This study provides a comprehensive summary of the neuro-oncology capacity in SSA. Next steps are to reach out to institutions who have registries and determine what data are being collected, with the hopes of defining a set of common elements to expand registry efforts across SSA. Similarly, to reach out to institutions that have ongoing brain tumor biobanks and CT/MRI capacity to determine what infrastructure exists.
Evaluating the current neuro-oncology capacity in Sub-Saharan Africa: A questionnaire-based survey
Odukoya, Lateef A , Cheserem, Beverly , Darko, Kwadwo , Ghomsi, Nathalie , Kabare, Gloria , Kamson, David , Eckel‐Passow, Jeanette E. , Jenkins, Robert B. , Decker, Paul A. , Kitange, Gaspar J. , Akinjo, Andrea O , Badmos, Kabir, Yevudza, W Elorm , Edrick, Elias, Katasi, Victoria Mwebe , Magambo, Margreth, Banti, Eyerusalem, Magoha, Michael, Ngaiza, Advera , Higgins, Dominique, Okemwa, Minda, Osei‐Tutu, Lawrence, Petershie, Bernard, Minja, Frank J. , Anunobi, C C , Tiamiyu, Liadi, Gankpé, Gbètoho Fortuné, Kwikima, Ugumba, Heronima, Kashaigili, Schroeder, Kristin, Thierry, Muanza, Davidson, Alan J. , Totimeh, Teddy , Gankpé, Fortuné Gbètoho , Schroeder, Kristin , Zerd, Francis , Odukoya, Lateef A , Cheserem, Beverly , Darko, Kwadwo , Ghomsi, Nathalie C , Kamson, David O , Eckel-Passow, Jeanette E , Jenkins, RB , Akinjo, Andrea O , Badmos, Kabir B , Yevudza, W Elorm , Bankole, Olufemi , Idowu, Olufemi E , Ayanlaja, Abiola Abdulrahman , Karekezi, Claire , Edrick, Elias , Ekhator, Chukwuyem , Huse, Jason T. , Magoha, Michael , Okemwa, Minda , Minja, Frank J , Etame, Arnold B , Kwikima, Ugumba Mussa , Schroeder, Kristin , Muanza, Thierry , Totimeh, Teddy , Balogun, James , Zerd, Francis , Decker, Paul A. , LLEWELLYN, HENRY J. , Idowu, Olufemi Emmanuel , Karekezi, Claire , Lachance, Daniel Honore , Banti, Eyerusalem, Nyalundja, Arsène Daniel , Etame, Arnold B. , Brown, Desmond , Davidson, Alan, Fonkem, Ekokobe

Mayo Clinic

Neuro-Oncology Practice | October 10, 2025 | Volume: 13 | Issue: 3 | Pages: 537-548

10.1093/nop/npaf107 | PMID 42131754 Get It

AbstractAbstract Background Central nervous system (CNS) tumors are a significant cause of morbidity and mortality in Sub-Saharan Africa (SSA). This project aimed to assess and map out the current neuro-oncology capacity in SSA, brain tumor registries, and biobanks. Methods This cross-sectional study utilized an online survey to gather data from healthcare professionals involved in CNS tumor care across SSA through the Society for Neuro-Oncology SSA (SNOSSA). The survey captured information on the availability of neuro-oncology practitioners, neuropathology, molecular diagnostics, cancer registries, and biobanking. Results A total of 145 respondents representing 70 healthcare institutions across 22 countries participated. Of the 70 institutions, specialties included neurosurgery (89%, 62/70), anatomic pathology (74%, 52/70), and medical oncology (71%, 50/70). For radiologic evaluation, 64% (45/70) of responding institutions reported having both CT and MRI. Access to molecular testing through immunohistochemistry or next-generation sequencing was available in 46% (32/70) of responding institutions. Multidisciplinary tumor boards were available for CNS cases in 86% (60/70) of responding institutions. Brain tumor-specific registries were available in 29% (20/70) of responding institutions, and 10% (7/70) maintained brain tumor biorepositories. Conclusion This study demonstrates that SSA has substantial potential in neuro-oncology care practice capacity and facilities. The most significant gaps were in neuropathology and molecular testing, which makes widespread implementation of the WHO 2021 diagnosis challenging. Understanding the prevalence of CNS tumor subtypes in SSA is difficult due to the low number of brain tumor registries and biobanks.
A Rapid Systematic Review of U.S. Food and Drug Administration–authorized COVID-19 Treatments
Sullivan, David , Franchini, Massimo , Focosi, Daniele , Sullivan, David J , Focosi, Daniele , Joyner, Michael J. , Casadevall, Arturo

Mayo Clinic

Open Forum Infectious Diseases | October 4, 2025 | Volume: 12 | Issue: 11 | Pages: No page available

10.1093/ofid/ofaf635 | PMID 41216419 Get It

A Cross‐Sectional Analysis of Social Determinants of Health in Bipolar Disorder: Exploring Gender‐Related Differences
Gardea‐Resendez, Manuel , Fuentes‐Salgado, Manuel, Romo‐Nava, Francisco , Prieto, Miguel L. , Bond, David J. , Betcher, Hannah K. , Moore, Katherine M. , Solares‐Bravo, Melissa , Ercis, Mete , Miola, Alessandro , Taylor-Desir, Monica , Frye, Mark A. , Solares-Bravo, Melissa , Ercis, Mete , Miola, Alessandro , Sanchez-Ruiz, Jorge A , Singh, Balwinder , Biernacka, Joanna , Taylor-Desir, Monica J., Frye, Mark , Romo-Nava, F , Bond, David J , Gardea-Resendez, Manuel , Özerdem, Ayşegül , Sánchez-Ruiz, Jorge A. , Veldić, Marin , Singh, Balwinder , Cuéllar‐Barboza, Alfredo B. , Coombes, Brandon J. , Biernacka, Joanna M. , McElroy, Susan L.

Mayo Clinic

Bipolar Disorders | September 12, 2025 | Volume: 27 | Issue: 8 | Pages: 545-550

10.1111/bdi.70062 | PMID 40936288 Get It

ABSTRACT Objectives To explore the clinical impact of social determinants of health (SDoH) stress in bipolar disorder (BD) course of illness and to explore potential gender differences in SDoH stress endorsement. Methods 2280 individuals living with BD type I or II (62% women; 67.5% BD‐I) participating in the Mayo Clinic Bipolar Biobank who completed a questionnaire assessing positive and negative‐valent stressors in the 12 months prior to study enrollment were included for this analysis. Six negative stressors were used as proxies of SDoH. Generalized linear models were used to test the association between SDoH stressors and markers of illness severity as well as potential differences by sex by including an interaction term. Results After adjusting for age, sex, and recruitment site, SDoH‐related stressors were significantly associated with a more severe course of illness in both men and women. Except for unemployment rates, women reported more frequently SDoH‐related stress (i.e., lack of family support, financial problems, health coverage and access problems). Conclusions The study found significant gender differences in both the endorsement of specific SDoH stressors and in the prevalence of specific illness severity markers; however, it did not directly test the predictive relationship between gender differences in SDoH and illness severity markers. Future studies aiming to achieve health equity in mental health care should continue assessing social determinants of health stressors, incorporating a gender perspective to better understand their influence on bipolar disorder.